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1. Introduction 
Studies on the mode of action of protein synthesis 
inhibitors can be chronologically divided into two 
periods. The first period covers the years 1951-1960 
and the second from 1961 until 1973. We make this 
chronological distinction because specific inhibition 
of bacterial protein synthesis by antibiotics (chlor- 
amphenicol and chlortetracycline) was first described 
in 195 1 [ 1,2] and confirmed in a ribosomal amino 
acid incorporation system directed by a specific syn- 
thetic polynucleotide as mRNA, in 1961 [3] . Since 
1961 studies on the mechanisms of antibiotic action 
have been so widely developed [4-6; reviews] that it 
became practically impossible to cover the subject in 
a single contribution, and protein synthesis inhibitors 
have usually been dealt with for the last eight years 
either in independent contributions or even in entire 
volumes [7- 121. This study will be concerned main- 
ly with advances in our knowledge of the mode of 
action, selectivity, and specificity of inhibitors of 
protein synthesis over the last ten years. However, a 
complete survey of the literature would not be 
possible in such a brief contribution as this. 
The process of protein biosynthesis can be arbi- 
trarily divided, for didactic purposes, into (a) steps 
taking place prior to translation and (b) steps in the 
translation mechanisms taking place at the ribosome 
level. 
2. Inhibitors of steps taking place prior to translation 
2.1. Inhibitors of aminoacyl-tRNA formation 
The synthesis of aminoacyl-tRNA, catalysed by 
North-Holland Publishing Company - Amsterdam 
the specific aminoacyl-tRNA synthetase, is a complex 
reaction involving the steps of activation and transfer: 
Activation: 
Amino -adid1 + Enzyme I t ATP Ms Enzyme 1 - 
aminoacyll -AMP + PPi 
Transfer: 
Enzyme 1 -aminoacyl 1 -AMP + tRNA 1 2 aminoacyl 1 - 
tRNAi t Enzyme, + AMP 
Inhibitors of these reactions have been recently 
reviewed [ 131. A number of amino acid analogues 
have been reported as inhibitors of the activation 
reaction by the corresponding aminoacyl-tRNA syn- 
thetases. Included in this group are 7-azatryptophan, 
tryptazan, 6-fluorotryptophan and 5-fluorotryp- 
tophan [ 141, norvaline, cu-amino-/3-chlorobutyrate, 
cw-aminobutyrate, selenomethionine, ethionine, nor- 
leucine [15-l 71, a number of tyrosine analogues 
[18], the methyl and ethyl esters of serine [ 191 and 
certain lysine analogues [20]. Some competitive 
inhibitors of certain amino acid(s) in the activation 
step become attached to tRNA in the transfer reac- 
tion and abnormal proteins are formed in subsequent 
incorporation. This has been observed with ethionine, 
norleucine [ 17,21,22], alloisoleucine, azetidine- 
carboxylic acid, canavanine, N-ethylglycine and 
O-methyl threonine [ 131. On the other hand, a num- 
ber of competitive inhibitors of amino acid activation 
block the formation of a specific aminoacyl-tRNA. 
This is so with the antibiotics borrelidin, which has 
been shown to prevent threonyl-tRNA formation in a 
number of bacterial species [23,27], and furano- 
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mycin, which inhibits isoleucyl-tRNA formation in 
bacterial and mammalian cells [25,26], whereas 
minosine likewise blocks phenylalanyl-tRNA synthe- 
sis [27]. Similarly, ten aminoalkyl-adenylates have 
been synthesized and shown to compete specifically 
with their corresponding amino acids and with ATP 
in the activation step, whereas their amino alcohols 
are, by themselves, inert competitive inhibitors of 
both amino acid activation and the transfer step 
[28,29]. 
An increasing number of oligonucleotides and 
polynucleotides have been used as analogues of some 
parts of the tRNA molecule to inhibit aminoacyl- 
tRNA formation since Hayashi and Miura [30] ob- 
served that some rRNA-derived oligonucleotides 
inhibit valyl-tRNA formation. There are abundant 
data in this field reporting competitive inhibition of 
specific aminoacyl-tRNA formation by certain poly- 
nucleotides. However, there are many contradictory 
reports, probably owing to uncertainty about the 
purity of nucleotides and aminoacyl-tRNA synthetases 
used, a point which is discussed elsewhere [ 131. 
From the data presented above it is obvious that 
some of the known inhibitors of aminoacyl-tRNA 
formation may useful for studying individual reac- 
tions in some purified cell-free systems, but in most 
cases they have neither a specific effect on this step 
nor a selective action on certain types of cells, nor 
can they even be used with intact cells. Therefore 
their importance as protein synthesis inhibitors is not 
very great, with the possible exception of some amino 
acid analogues, minosine [27] and the antibiotics 
borrelidin [23,24] and furanomycin [25,26]. 
2.2. Inhibitors of f-Met-tRNAF formation 
Biosynthesis of the initiator fV-formyl-Met-tRNAF 
takes place according to the reaction: 
Met-tRNAF+N”-formyl-H4 folateZJV-formyl-Met- 
tRNAF+H4 folate 
in which the o-NH2 group of the methionine of Met- 
tRNAF is the acceptor group, the donor is Ni” - 
formyl-H4 folate and the enzyme catalysing the reac- 
tion is N” -formyl-H4 folate-methionyl-tRNAF trans- 
formylase. Hence, inhibition of f-Met-tRNAF forma- 
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tion can take place by blocking either N”-formyl-H4 
folate formation or the transformylase. 
N” -Formyl-H4 folate synthesis is inhibited by a 
number of dihydrofolate analogues such as amino- 
pterin, amethopterin (synonym methotrexate) and 
pteroylaspartic acid. Aminopterin has indeed been 
shown to block the f-Met-tRNAF required for initia- 
tion of protein synthesis in mitochondria without 
affecting cytoplasmic protein synthesis in mammalian 
cells [31]. Because of the permeability barriers for 
these drugs in a number of organisms, simpler com- 
pounds have been synthesized, including pyrimeth- 
amine and trimethoprim [32]. Indeed, in E. coli 
trimethoprim blocks the synthesis of &galactosidase 
and phage Tq proteins. 
Furthermore, extracts of trimethoprim-treated 
bacteria require the addition of f-Met-tRNAP to 
initiate protein synthesis [33,34] . 6-Chloro-8-aza-9- 
cyclopentylpurine and a number of related com- 
pounds are also inhibitors of N” -formyl-H4 folate 
formation, and therefore block DNA, RNA and pro- 
tein synthesis in E. coli [35,36]. 
The catalytic action of the N” -formyl-H4 folate- 
methionyl-tRNAF transformylase can be inhibited by 
either N” -formyl-H4 folate analogues, of Met-tRNA, 
analogues, or compounds which deplete the pool of 
the substrates of the reaction. Indeed, a number of 
pteridine derivatives have been shown to block the 
formylation reaction by competing with Ni”-formyl- 
H4 folate [37,38]. 
Hydroxylamine is known to block DNA, RNA and 
protein synthesis, but when added at low concentra- 
tions to growing bacterial cultures, it specifically 
blocks the initiation phase of protein synthesis [34]. 
This is due to the reaction of hydroxylamine with the 
formyl residue of 5,1 0-methylene-H4 folate, leading 
to the formation of a folmaldoxine and depleting the 
pool of N” -formyl-H4 folate which is the precursor 
of 5,1 0-methylene-H4 folate [40] . 
Inhibitors of f-Met-tRNAF formation inhibit the 
initiation of translation in bacteria, blue green algae, 
mitochondria and chloroplasts, but not in eukaryotic 
systems, since f-Met-tRNAF is not an initiator in 
these systems. In any case, care has to be taken in the 
use of inhibitors of dihydrofolate reductase and iV” - 
formyl-H4 folate transformylase in intact bacteria as 
specific inhibitors of protein synthesis, since they can 
also block many other cell processes. 
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3. Inhibitors of translation 
3.1. Translation of mRNA 
The translation of mRNA into protein, which 
takes place at the ribosome level, can be divided into 
three phases: initiation, elongation and termination. 
The overall reactions taking place in the process of 
translation by bacterial and eukaryotic ribosomes are 
shown schematically in figs. 1 and 2, according to the 
translocation mode with one single entry site on the 
small subunit. 
A single entry site on the small ribosome subunit is 
favoured in studies with a number of protein synthe- 
sis inhibitors, since all these compounds preventing 
mRNA-directed f-Met-tRNAF binding to the small 
ribosome subunit (step (b)) are equally active in 
preventing aminoacyl-tRNA binding (step (d)). For 
the purpose of understanding the whole process, it 
can be divided into three phases: initiation, elonga- 
tion and termination (figs. 1 and 2). 
In the initiation phase we have to distinguish three 
steps: (a) recognition of initiation factors and mRNA 
by the small subunit, (b) binding of the initiator and 
(c)joining to the complex of the larger subunit 
(fig. 1). 
This step (c) involves two reactions; in the first, 
the larger subunit is attached to the initiation com- 
plex (step (cr)), and the other, requiring GTP hy- 
drolysis (step (cZ)), in which the 3’ end of f-Met- 
tRNAP binds to the donor-site of the peptidyl- 
transferase centre and the antidocon interaction with 
the small subunit is interrupted, leaving the site open 
for the entry of aminoacyl-tRNA to start the elonga- 
tion phase. The initiation phase has not been well 
resolved in mammalian systems, but for comparative 
purposes we have assumed that a similar sequence of 
reactions takes place (fig. 2). This might not be en- 
tirely correct, since the initiator appears to bind to 
mammalian ribosomes (step (b)) prior to mRNA 
recognition (step a(a), fig. 2) [41,42]. 
The elongation phase is composed of repeated 
cycles of elongation. Steps (d) EF T- (or EF l)-depen- 
dent aminoacyl-tRNA binding, (e) peptide bond 
formation and (f) translocation, can be distinguished 
in each elongation cycle. In the translation process 
there are as many elongation cycles as there are pep- 
tide bonds to be formed in order to synthesize the 
protein (figs. 1 and 2). There is evidence for only a 
single entry site in the small subunit, and therefore 
for the codon-anticodon interaction of the incoming 
aminoacyl-tRNA (step (d)), the anticodon interaction 
of either f-Met-tRNAF or peptidyl-tRNA in the small 
subunit has to be interrupted. The specific step of 
peptide bond formation (step (e)) is catalysed by the 
peptidyl transferase centre, which is an integral part 
of the larger ribosomal subunit. The translocation 
step requires one of the elongation factors and in- 
volves movement of the peptidyl-tRNA from the 
A-site to the P-site, coupled with GTP hydrolysis and 
release of the uncharged tRNA. 
The termination phase takes place when a chain- 
terminating codon (nonsense codon) (either UAA or 
UAG or UGA) is recognized and cleavage of the bond 
between the peptidyl and tRNA moieties takes place 
in a reaction catalysed by the ribosomal peptidyl 
transferase centre requiring the release factors (g). 
3.2. Selectivity of protein synthesis inhibitors 
Early studies on [14 Clchloramphenicol binding 
showed that this antibiotic binds to all classes of 
ribosomes of the 70 S type which were tested, but 
does not bind to any of the 80 S type ribosomes 
studied [43]. A similar finding was later observed 
with a number of antibiotics, whereas others have a 
much wider spectrum. Since there are at least two 
types of systems for protein synthesis, their inhibitors 
can be classified, according to their specificity, into 
those affecting systems of (a) the prokaryotic type, 
(b) the eukaryotic type and (c) the prokaryotic and 
the eukaryotic types (table 1). In general antibiotics 
affecting prokaryotic-type systems are active in bacte- 
ria, blue-green algae, mitochondria and chloroplast, 
whereas those acting selectively on eukaryotic-type 
systems are active in all types of cells having 80 S 
type ribosomes. However, there are a few important 
cases in which some antibiotics appear to have a nar- 
rower spectrum of selectivity. Thus, tenuazonic acid 
inhibits protein synthesis by mammalian but not by 
yeast ribosomes [44] ; erythromycin, lincomycin and 
paromomycin inhibit protein synthesis by bacteria 
but not by rat liver mitochondria [39 I] ; and al- 
though fusidic acid is active in prokaryotic and euka- 
ryotic systems it has been reported to be inactive in 
Neurospora crassu mitochondria [45] and in protein- 
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Table 1 
Inhibitors of protein synthesis 
23 March 1974 
Acting on prokaryotic systems Acting on prokaryotic and eukaryotic systems (continued) 
Althiomycin 
Bacteriocin DF 13 
Berninamycin 
Chloramphenicol group: 
Chloramphenicol 
D-AMP-3 
d-Thiomycetin 
D-Win-5094 
Colicin Es 
Kasugamycin 
Lincomycin group: 
Celesticetin 
Clindamycin 
Lincomycin 
Macrolides group: 
Angolamycin 
Carbomycin 
Erythromycin 
Forocidin 
Lancamycin 
Leucomycin 
Methymycin 
Neospiramycin 
Oleandomycin 
Spiramycin 
Tylosin 
Micrococcin 
Multhiomycin 
Rubradirin 
Spectinomycin 
Streptogramin A group: 
Ostreogrycin G 
Streptogramin A 
Streptogramin B group: 
Staphylomycin S 
Streptogramin B 
Viridogrisein 
Streptomycin group: 
Gentamycin 
Hygromycin B 
Kanamycin 
Neomycin 
Paromomycin 
Streptomycin 
Thiostrepton group: 
Siomycin 
Sporangiomycin 
Thiopeptin 
Thiostrepton 
Viomycin 
Acting on prokaryotic and eukaryotic systems 
Actinobolin Nucleocidin 
Adrenochrome Pactamycin 
Amicetin Polydextran sulphate 
Aurintricarboxylic acid Polyvinyl sulphate 
Blasticin S Puromycin 
synthesizing systems from sporulating Bacillus subtilis 
[45a]. 
3.3Jnhibitors of the initiation phase 
Step (a> 
Polydextran sulphate [46,47] , polyvinyl sulphate 
Bottromycin As 
Chartreusin 
Edeine A 1 
Fusidic acid 
Gougerotin group: 
Bamicetin 
Gougerotin 
Plicamicetin 
Pyrochatechol Violet 
Sparsomycin 
Tetracycline group: 
Chlortetracycline 
Doxycycline 
Oxytetracycline 
Tetracycline 
Tosylphenylalanylchloro- 
Guanylyl-methylene- 
diphosphonate 
methane 
Acting on eukaryotie systems 
Abrin 
Anisomycin 
Diphtheria toxin 
Emetine 
Enomycin 
Glutarimide group: 
Actiphenol 
C zloheximide 
Streptimidone 
Streptovitacin A 
MDMP 
Pederine 
Phenomycin 
Ricin 
Sodium fluoride 
Tenuazonic acid 
Trichodermin group: 
Crotocin 
Crotocol 
Fusarenon X 
Nivalenol 
Trichodermin 
Trichodermol 
Trichothecin 
Verrucarin A 
Verrucarol 
Tubulosine 
Tylophora alkaloids: 
Cryptopleurine 
Tylocrebrine 
Tylophorine 
[48], aurintricarboxylic acid [49,50] and Pyrochate- 
chol Violet [51] used at low concentrations in cell- 
free systems interact specifically with the small ribo- 
some subunit and prevent mRNA or synthetic poly- 
nucleotide binding to the subunit. Aurintricarboxylic 
acid has been widely used as an inhibitor of initiation 
and has been reported to block not only mRNA bind. 
ing to the ribosomes [50,52,53], but also formation 
S68 
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of a ternary complex 1-GTP-Met-tRNA, [54], dis- 
sociation of free ribosomes into their subunits [55], 
EF G and ribosome-dependent GTPase [56] and the 
function of EF Ts [57]. Therefore aurintricarboxylic 
acid inhibits initiation and elongation. However, at 
low concentrations, this drug can be used as a selec- 
tive inhibitor of the initiation phase in bacterial as 
well as eukaryotic systems [52, 58-611. 
Step (b) 
The main target of edeine A, in intact bacteria is 
DNA synthesis [62,63]. However, in cell-free systems 
edeine Al can be used as an instrument in protein 
synthesis since it interacts with both ribosomal sub- 
units, but it has a preferential affinity for the small 
subunit [64-661. The main effect of edeine is to 
prevent binding of the initiator substrate [65,67 ] . 
The aminoglycoside antibiotic kasugamycin does 
not possess the characteristic dihydrostreptamine or 
streptamine moiety which is common to all amino- 
glycoside antibiotics causing misreading. Therefore 
kasugamycin does not cause misreading, but acts on 
the 30 S ribosome subunit [68] by preventing the 
binding of f-Met-tRNAF [69] . Resistance to kasuga- 
mycin in E. coli is due to a lack of methylation of 
two adjacent adenine residues in the 16 S rRNA of 
the 30 S subunit [69,70]. Furthermore, an altered 
ribosomal protein (S4) has been observed in kasuga- 
mycin-resistant mutants [7 l] . 
SW (4 
Sodium fluoride causes polysomal dissociation and 
accumulation of ribosomes or ribosomal subunits 
[72-751. The initiation complex with the 40 S ribo- 
somal subunits appears to be normally formed in the 
presence of sodium fluoride, but this compound 
prevents the su.bsequent binding of the 60 S subunit 
[53,76]. A similar mechanism of action has been 
proposed for the herbicide MDMP (2-(4-methyl-2,6- 
dinitroanilino)~N-methylpropionamide) [77]. 
The antibiotic streptomycin affects a number bf 
cell processes other than protein synthesis [7]. Never- 
theless, we will restrict our discussion to the effects 
of the antibiotic as a known inhibitor of protein 
synthesis [78,79]. Streptomycin was found to cause 
misreading in translation early on in intact bacteria 
[80] as well as in cell-free systems [81]. The effect 
of streptomycin is located in the bacterial ribosome 
[81-841 in the 30 S subunit [85,86]. One of the 
30 S ribosomal proteins (S4) is altered in strepto- 
mycin-resistant mutants [87] and leads to resistant 
ribosomes in reconstitution experiments. In fact, the 
antibiotic binds to sensitive ribosomes [88] and the 
30 S subunit from sensitive [89-911 but not resis- 
tant ribosomes [91]. Misreading is not, however, the 
main effect of streptomycin in protein synthesis, 
since the antibiotic inhibits the translation process in 
the initiation phase [92-951. Streptomycin does not 
prevent the joining of the 50 S subunit to the initia- 
tion complex formed on the small subunit (fig. 1~~) 
but the initiation complex formed in the presence of 
streptomycin is unstable and the subsequent binding 
of aminoacyl-tRNA does not take place (step (d,)) 
[96]. Therefore streptomycin appears to block reac- 
tion (cz) (fig. 1). Streptomycin also inhibits elonga- 
tion by preventing aminoacyl-tRNA binding to the 
A-site (step(d)) [95], and termination by preventing 
recognition of RF 1 or RF 2 [97]. These effects are 
evidently related to the same interaction of strepto- 
mycin with the ribosomal30 S subunit which causes 
inhibition of initiation. However, many other effects 
of streptomycin (‘stuck’ 70 S ribosomes, inhibition of 
ribosome dissociation, killing effect, etc.) might or 
might not be related to the inhibitory effect of the 
antibiotic in the last reaction of the initiation phase 
[lo-12; reviews]. 
A number of other aminoglycoside antibiotics 
(gentamycin, hygromycin B, kanamycin, neomycin 
and paromomycin) cause misreading in intact bacteria 
[98] and cell-free systems [99,100] and act on the 
30 S ribosomal subunit at or near the streptomycin 
site [ 1011. Tobramycin also causes misreading in bac- 
terial cell-free systems (San Millan, M.J. and Modolell, 
J., unpublished observations). 
Pactamycin blocks protein synthesis by bacterial 
and mammalian systems [ 102,103] by interacting 
with the ribosomes [ 1041 in one site on the smaller 
subunit [ 105,106] . Studies on bacterial and mamma- 
lian systems suggest hat pactamycin is an inhibitor of 
the initiation phase [ 107-1091. Steps (a)-(cl) are 
not inhibited by pactamycin, since the initiation 
complex is formed but the substrate is not reactive 
with puromycin, and therefore it is likely that the 
antibiotic blocks step (cz) [ 1 lo- 1121. At higher 
S69 
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concentrations pactamycin also inhibits elongation, 
probably owing to a second site interaction of the 
antibiotic [ 1061. 
SW (4 
The tetracycline antibiotics block protein synthe- 
sis by bacterial and mammalian systems [ 113 ,114] . 
Early works on tetracycline binding showed many in- 
teraction sites of the antibiotic with both ribosomal 
subunits [ 115- 1171. Since these antibiotics were 
found to prevent non-enzymic binding to bacterial 
ribosomes [ 118,119] and to their 30 S subunits 
[66,120,121] , it was assumed that the main effect of 
these antibiotics was on the small ribosomal subunit. 
However, the EF T-dependent binding of aminoacyl- 
tRNA is inhibited by much lower concentrations of 
the tetracyclines than the non-enzymic binding 
[ 122- 1251. The EF T-dependent GTP hydrolysis is 
not affected by the tetracyclines [93-9.51. This en- 
zymic binding is obviously the step inhibited by the 
tetracyclines. However, it is not yet clear whether the 
interactions of these antibiotics with the smaller or 
the larger ribosomal subunit are more relevant for 
their inhibitory effect on protein synthesis. Since EF T 
interacts with the 50 S subunit [ 1231, and recent 
binding studies with tetracycline suggest hat its inter- 
action with the 50 S subunit might be more relevant 
for the antibiotic action [127,128]. Tetracycline has 
also been shown to block the termination phase of 
protein synthesis, probably by preventing the recogni- 
tion of the release factors [ 129,130] . 
Antibiotics of the thiostrepton group include thio- 
strepton (synonyms, bryamycin and thiactin) and the 
related compounds siomycin, thiopeptin and sporan- 
giomycin, all of which appear to have a similar mode 
of action. Early genetic studies suggested that thio- 
strepton action might be located on the ribosome 
[ 13 l] . This was confirmed by biochemical studies 
and these antibiotics were shown to interact with the 
50 S subunit [ 132- 1351. These antibiotics inhibit 
translocation [133,136] and EF G-dependent GTP 
hydrolysis [ 134,137- 1391 in model systems by 
preventing interaction of EF G with the ribosome 
[134] , and were therefore postulated as specific 
inhibitors of the translocation step. However, it was 
observed in further studies that the thiostrepton 
antibiotics inhibit both enzymic [126,138] and non- 
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enzymic binding of aminoacyl-tRNA to the ribosomal 
A-site in cell-free systems [126,139]. Indeed, com- 
parative studies showed that these antibiotics inhibit 
the EF G-dependent reaction and EF T-dependent 
binding of aminoacyl-tRNA in cell-free systems 
[126,139,140] and in intact bacteria [141] to a 
similar extent. Unlike the tetracyclines, the thiostrep- 
ton antibiotics block the GTP hydrolysis coupled to 
EF T-dependent aminoacyl-tRNA binding [ 1261. 
Since thiostrepton does not inhibit translocation in 
intact bacteria [141, 1421, the main target reaction 
of the antibiotic is the aminoacyl-tRNA binding 
[ 126,143] . The non-enzymic binding of aminoacyl- 
tRNA to the A-site is sensitive to siomycin 
[ 126,139] , whereas the uncoupled EF Tu-dependent 
GTP hydrolysis is insensitive to thiostrepton [144] , 
indicating that the antibiotics block the A-site on the 
50 S subunit competing with EF G and aminoacyl- 
tRNA. Furthermore thiostrepton enhances uncoupled 
EF T- or EF G-dependent GTP hydrolysis by 50 S- 
derived cores lacking the ribosomal proteins L7 and 
L12 [ 1451, showing that these proteins are not di- 
rectly involved in the binding of the antibiotic 
[146,147]. There is one report in which inhibition of 
IF 2-dependent GTP hydrolysis by thiostrepton was 
observed [ 1481, which would favour the possibility 
of a single GTPase centre on the ribosome, as previ- 
ously suggested [126,143] . 
Fusidic acid was shown to prevent translocation, 
EF G- and EF 2-dependent GTP hydrolysis by bac- 
terial and mammalian cell-free systems [ 149- 1531. 
However, EF G-dependent GTPase is resistant to the 
antibiotic in mutants resistant to fusidic acid [ 154- 
1561 . EF G as a target for the antibiotic action was 
also suggested by preliminary binding experiments 
using the tritiated antibiotic [ 1571. In the presence 
of ribosomes, GTP and either EF G or EF 2, fusidic 
acid forms a stable complex fusidic acid-GDP- 
ribosome-EF G (or EF 2), which appears to account 
for the inhibitory effect of the antibiotic on trans- 
location [ 158,159]. There is, however, increasing 
evidence that the primary effect of fusidic acid on 
protein synthesis in intact cells is not the inhibition 
of translocation: for fusidic acid-inhibited polysomes, 
formed on synthetic or viral RNA or an endogenous 
messenger, have their nascent peptides in the puro- 
mycin-reactive position [ 142,160- 1621. Further- 
more, formation of the complex GDP-ribosome- 
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fusidic acid-EF G [ 163- 1661 prevents aminoacyl- 
tRNA binding. Essentially similar results were obtain- 
ed in studying aminoacyl-tRNA binding when the 
complex GDP-EF 2-ribosome-fusidic acid 
[ 167,168] was formed. Inhibition of aminoacyl- 
tRNA binding by fusidic acid appears to be a con- 
sequence of its effect in sequestring all the EF G or 
EF 2 available, owing to the formation of the GDP- 
ribosome-fusidic acid-EF G (or EF 2) complex, as 
postulated, [ 162,163] since the effect of the anti- 
biotic in cell-free systems can be decreased or abolish- 
ed by saturating concentrations of EF G [ 1691 or EF 
2 [ 1671, but can be enhanced by increasing the con- 
centration of free ribosomes [ 1671. 
Step (e) 
Puromycin is an analogue of the 3’ terminal end of 
aminoacyl-tRNA [ 1701. However, puromycin lacks 
that part of the aminoacyl-tRNA molecule responsi- 
ble for interaction with template and the small ribo- 
somal subunit. Because of this, the use of puromycin 
provides a simplified method for the study of peptide 
bond formation in a reaction in which the o-NH* 
group of puromycin becomes linked to the C-terminal 
end of f-Met- or the peptidyl group (‘puromycin 
reaction’). The product of the puromycin reaction 
(f-Met- or peptidyl-puromycin) is unable to take part 
in the next step of protein synthesis. However, all the 
evidence indicates that the formation of a peptide 
bond between puromycin and the f-Met or peptidyl 
group takes place by the same mechanism as peptide 
bond formation in protein synthesis [ 17 1,172] . Poly- 
phenylalanyl-tRNA [ 172,173] , polylysyl-tRNA 
[174,175], f-Met-tRNAF [176,177] and Ac-Phe- 
tRNA [ 1521 are suitable donor substrates in the 
puromycin reaction. The terminal fragments 
CACCA-, AACCA-, ACCA- and CCA-Met-f from 
f-Met-tRNAF undergo a ribosome-catalysed reaction 
with puromycin to yield f-Met-puromycin in a simpli- 
fied system known as the ‘fragment reaction’. The 
reaction requires only the large ribosomal subunit, 
monovalent and divalent cations and either methanol 
or ethanol [ 178,179]. The small ribosomal subunit or 
mRNA is not required, but they can stimulate the 
peptidyl transferase activity of the large subunit in 
certain experimental systems [ 1801. The structural 
requirement for puromycin-like activity as an ac- 
ceptor substrate has been studied by using a ‘number 
of puromycin derivatives and aminoacyl-nucleosides 
[ 18 l-l 871. In cell-free systems Phe-, Tyr- and Leu- 
adenosine are as active as puromycin as acceptor sub- 
strates in the peptide bond formation reaction [ 182- 
1861. The puromycin derivatives cz-hydroxy- and 
demethoxy-cr-hydroxypuromycin are of special sig- 
nificance. These compounds lack the a-amino group 
of puromycin and are therefore unable to form a 
peptide bond, but they form an ester bond with the 
f-Met moiety of f-Met-tRNA or CAACCA-Met-f 
in a reaction catalysed by the peptidyl transferase 
centre of the ribosome [ 1881. The kinetics of the 
puromycin reaction have been studied in the ‘frag- 
ment reaction’ assay and in a polysomal system [ 189, 
1901. There is a weak interaction of puromycin with 
the acceptor site of the peptidyl transferase centre 
which is inhibited by Phe-adenosine [191]. Reports 
on affinity labeling studies of puromycin derivatives 
have appeared [ 192,193], one of them suggesting 
that Br-puromycin binds to the RNA of the larger 
ribosome subunit [ 1931. 
Inhibition of protein synthesis by chloramphenicol 
was shown in earlier work, in intact bacteria [ 1,2] 
and confirmed in different cell-free systems [3,194- 
1961. The antibiotic binds to ribosomes from bac- 
teria [ 1971, chloroplasts and blue-green algae 
[198,199] on the 50 S ribosome subunit [200]. One 
binding site for the antibiotic on the ribosome was 
initially proposed [201-2031 and subsequently dem- 
onstrated [204], but two binding sites have also been 
proposed [202,205]. Chloramphenicol is an inhibitor 
of peptide bond formation, as is shown by studies in 
intact bacteria [ 1031 and cell-free systems [206- 
21 l] . This was in fact observed in many systems, 
since chloramphenicol prevents the reaction of either 
polyphenylalanyl-tRNA [ 17 1- 1731, or polylysyl- 
tRNA [ 174,175,206,207] , or f-Met-tRNAF [208] , 
or Ac-Phe-tRNA [175,209-2111, or dipeptidyl- 
tRNA [211], with puromycin. However, the most 
conclusive evidence for the inhibitory effect of chlor- 
amphenicol on the peptidyl transferase centre was 
observed in the ‘fragment reaction’ [212,213] , since 
it is the most fully resolved assay for peptide bond 
formation. The inhibitory effect of chloramphenicol 
in this system was found to be a mixed competitive 
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effect for puromycin [ 1891, which is in agreement 
with previous results on the puromycin reaction 
[206], although the same conclusions were not 
reached by another group [214,2 151. Indeed chlor- 
amphenicol was found to have no effect on substrate 
binding (CACCA-Leu-Ac) to the donor site of the 
peptidyl transferase centre [213-2151, but it inhibits 
binding of either puromycin [I911 or aminoacyl- 
oligonucleotides to the acceptor site of the active 
centre [ 2 18-2221. Studies on reconstitution and 
affinity labeling suggest hat protein L16 is involved 
in chloramphenicol binding [223,224] . 
Lincomycin inhibits protein synthesis by bacteria 
and bacterial cell-free systems [196,225,226], the 
antibiotic interacting with the larger ribosomal sub- 
unit [ l96,204,226,226a]. Lincomycin affinity to 
ribosomes from Gram-negative bacteria is very slight 
[226], but this affinity is considerably increased in 
the presence of ethanol [204]. Lincomycin inhibits 
peptide bond formation [2 131 and prevents binding 
of the 3’ terminal end of substrates to the donor 
[216-2181 and to the acceptor [218,221,222] site 
of the peptidyl transferase centre. 
Antibiotics of the streptogramin A group (strepto- 
gramin A, mikamycin A, virginiamycin Mr , verna- 
mycin A, ostreogrycin A, synergistin A) inhibit pro- 
tein synthesis by bacteria and bacterial cell-free sys- 
tems [ 197,227-2321, by preventing peptide bond 
formation, as shown in the ‘fragment reaction’ assay 
[213] and confirmed in other systems [209,233]. 
These antibiotics interact with the 50 S ribosome 
subunit [64,197,234] and prevent binding of 
CACCA-Leu-AC to the donor-site [216,2 171 end of 
aminoacyl-oligonucleotides to the acceptor-site 
[219-2221 of the peptidyl transferase centre. They 
have also been reported to inhibit EF T-dependent 
aminoacyl-tRNA binding without affecting the GTP 
hydrolysis [ 126,235] and non-enzymic binding of 
f-Met-tRNAF [236]. These effects might be due to 
the inhibition by these antibiotics of binding of the 3’ 
terminal end of the substrates, as indicated above. 
Indeed these results may also explain the reported 
polysome breakdown by these antibiotics [237,238], 
which is contrary to the results observed with most of 
the inhibitors of peptidyl transferase. 
The macrolide antibiotic spiramycin III and its 
derived compounds neospiramycin III and forocidin 
III have been shown to block protein synthesis by 
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intact bacteria [239] and bacterial cell-free systems 
[ 196,239]. There is ample evidence for the interac- 
tion of spiramycin III with the larger ribosomal sub- 
unit of sensitive bacteria [64,197,239-2421. Spira- 
mycin-resistant mutants do not bind the antibiotic 
[242] and have an altered protein L4 [243]. Spira- 
mycin III blocks peptide bond formation in different 
experimental systems [209,2 11,2 13,244,245] , al- 
though it is a very poor inhibitor of the puromycin 
reaction when f-Met-tRNAF is used as the donor 
substrate [246] . Binding of both the donor [2 16- 
2181 and the acceptor [219-2221 substrate to the 
peptidyl transferase centre is inhibited by the anti- 
biotic. Spiramycin III, like streptogramin A, causes 
polysome breakdown [237]. The macrolide anti- 
biotics carbomycin, leucomycins, niddamycin, tylosin 
and relomycin appear to have a mode of action simi- 
lar to that of spiramycin III [196,197,211,213,244, 
246,247]. 
With the single exception of puromycin, the pep- 
tidy1 transferase inhibitors mentioned above act selec- 
tively on ribosomes of the prokaryotic type, whereas 
amicetin [248-2521, gougerotin [250,253-2561, 
blasticidin S [251,257-2591, actinobolin [25 1,252, 
2601 and sparsomycin [ 102,261,262] act on ribo- 
somes of the prokaryotic and the eukaryotic type. 
Sparsomycin is the best known antibiotic of this 
group. It acts on the ribosome [263] in the larger 
ribosome subunit [213] and it has a reduced inhibito- 
ry effect on chloramphenicol binding [205,264]. 
Sparsomycin is an inhibitor of the peptide bond for- 
mation step since it inhibits the puromycin reaction 
in bacterial [206,265-2671, yeast [251], mamma- 
lian [252] and mitochondrial ribosomes [268]. Fur- 
thermore, sparsomycin is a powerful inhibitor of the 
‘fragment reaction’ assay by bacterial [213] , yeast 
[251] and mammalian [252,269] ribosomes. Sparso- 
mycin appears to act on the acceptor-site of the pep- 
tidy1 transferase centre since it inhibits, to a certain 
extent, EF T-dependent binding of aminoacyl-tRNA, 
uncoupling GTP hydrolysis [270] , and also prevents 
binding of CACCA-Phe [220,221,271]. On the 
other hand, sparsomycin enhances non-enzymic bind- 
ing of Ac-Phe-tRNA to the donor site [272], even in 
the absence of any mRNA [273,274], and CACCA- 
Leu-AC [275]. Amicetin, actinobolin, blasticidin S 
and gougerotin also inhibit peptide bond formation in 
the puromycin [209,249,265,276,277] and the frag- 
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ment [213,25 1,278] reaction assays. These anti- 
biotics resemble sparsomycin in their mode of action, 
although they are less active. These antibiotics have 
some inhibitory effect on binding of the acceptor 
substrate [220,221,271,277,278], and enhance bind- 
ing of the donor substrate [216,217,277,278] to the 
peptidyl transferase centre. Furthermore, blasticidin 
S binds to the larger ribosomal subunit; and this bind- 
ing is inhibited by gougerotin [279] while, converse- 
ly, gougerotin binding to the ribosome is prevented 
by blasticidin S and also by actinobolin, amicetin and 
sparsomycin (Barbacid, M. and Vazquez, D., unpub- 
lished observations). 
Anisomycin inhibits protein synthesis by eukaryo- 
tic systems [280,281] specifically blocking peptide 
bond formation in the ‘fragment reaction’ [ 179,25 1, 
252,269] and in the puromycin reaction [252] as- 
says. Anisomycin was reported to be a competitive 
inhibitor of puromycin [282] . Anisomycin specifical- 
ly binds to the 60 S ribosome subunit; this binding is 
inhibited by trichodermin and tenuazonic acid (Bar- 
bacid, M. and Vazquez, D., unpublished observa- 
tions). 
Sesquiterpene antibiotics of the trichodermin 
group are also specific inhibitors of protein synthesis 
by 80 S type ribosomes [283-2861. These anti- 
biotics inhibit the puromycin and the ‘fragment reac- 
tion’ assays [285]. Trichodermin binds to the 60 S 
ribosomal subunit and this binding is inhibited by 
anisomycin and tenuazonic acid (Barbacid, M. and 
Vazquez, D., unpublished observations). All the ex- 
perimental evidence suggests that the trichodermin 
antibiotics act on the same ribosomal site as aniso- 
mycin. 
Tenuazonic acid acts on the 60 S ribosome subunit 
at the same site as anisomycin and trichodermin. 
Therefore it is an inhibitor of mammalian protein 
synthesis [287], which specifically prevents peptide 
bond formation [44,252,269] . A very important 
characteristic of tenuazanic acid is the preferential in- 
hibition in mammalian systems, since the antibiotic 
has less effect on plant ribosomes and no significant 
effect on yeast ribosomes, as has been determined by 
studying inhibition on protein synthesis [44] and on 
[3H]anisomycin binding [288]. 
Griseoviridin is an interesting antibiotic which has 
been considered as an antibacterial agent since it is 
not active on any of the cells of the eukaryotic type 
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in which it has been tested 2891. However, griseoviri- 
din is an active inhibitor of protein synthesis in mam- 
malian systems [288]. This antibiotic prevents pep- 
tide bond formation by bacterial [290] and mamma- 
lian ribosomes [288]. Furthermore, griseoviridin has 
a unique synergistic effect with gougerotin at the 
ribosome level, since it enhances the binding of this 
antibiotic in cell-free systems up to 400% (Barbacid, 
M. and Vazquez, D., unpublished observations). 
In view of what is known about the mode of ac- 
tion of antibiotics acting on the peptidyl transferase 
centre and the different studies on antibiotic com- 
petition for binding sites, the site of action of these 
antibiotics on the larger subunit can be represented 
schematically in bacterial (fig. 3) and mammalian 
(fig. 4) ribosomes. Although erythromycin is not 
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Fig. 4. 
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considered as an inhibitor of peptide bond formation, 
it is presented as overlapping the binding sites of 
chloramphenicol and lincomycin, since it blocks 
binding of these antibiotics [197,264] and prevents 
their effect on the peptidyl transferase centre [2 16, 
226a,291]. 
Step 09 
Erythromycin inhibits protein synthesis in intact 
bacteria and bacterial cell-free systems [196,292, 
2931. One molecule of erythromycin binds to sensi- 
tive ribosomes on the larger subunit [292,294-2971. 
It prevents chloramphenicol [197],lincomycin [226a] 
and spiramycin III [239] binding and vice versa 
[204]. These results and the reported inhibition of 
erythromycin on the puromycin [2 10,2 11,244,245, 
2981 and the fragment [247] reaction assays when 
certain donor substrates are used, suggest hat 
erythromycin is an inhibitor of peptide bond forma- 
tion. However, erythromycin does not inhibit peptide 
bond formation in most of the model systems. More- 
over, some studies in intact cells [ 1031 and cell-free 
systems [ 141,299,410] suggest hat erythromycin is 
an inhibitor of transloeation although it does not 
inhibit this step in most of the model systems. Clear- 
ly, the problem of erythromycin as an inhibitor of 
peptidyl transferase or translocation is still un- 
resolved. Some E. coli mutants resistant to erythro- 
mycin have been observed to have an altered L4 pro- 
tein and do not bind the antibiotic [300-3021. How- 
ever, in other resistant mutants protein L22 is altered, 
and yet erythromycin binds to the ribosome [303] . 
On the other hand, induced and constitutive resis- 
tance to the antibiotic has been associated with the 
modification of 23 S rRNA in which formation of 
dimethyladenine has been observed [304,305]. 
Although cycloheximide was earlier found specifi- 
cally to block eukaryotic protein synthesis by intact 
cells [306] and cell-free systems [ 104,307-3 lo], 
little is known about its controversial site and mode 
of action. Apart from protein synthesis, cyclo- 
heximide has an inhibitory effect on DNA and RNA 
synthesis [8] in certain intact cells. Furthermore, 
inhibition by cycloheximide of RNA polymerase I
from some fungi has been reported [3 11,3 121. Cer- 
tain results, initially obtained in hybridization experi- 
ments with cycloheximide-treated and untreated 
fractions, suggested the supernatant fraction as the 
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site of cycloheximide action [ 104,3 131, whereas 
similar experiments in more resolved systems suggest- 
ed the ribosome as the cycloheximide target [25 I] . 
Indeed, the ribosome is now widely accepted as the 
site of interaction of cycloheximide after hybridiza- 
tion experiments using strains resistant to the anti- 
biotic [314-3171. It was concluded that the 60 S 
subunit, but not the 40 S, is responsible for the resis- 
tance to the antibiotic [316,3 171. There is also dis- 
agreement concerning the reaction in protein synthe- 
sis inhibited by cycloheximide. Cycloheximide 
inhibits not only breakdown, but also reassembly of 
the polysomes [ 102,3 18-3201, and this suggests that 
it might inhibit more than one reaction. In fact cyclo- 
heximide, at low concentrations, prevents polysome 
formation, but inhibits translocation at higher con- 
centrations [32 I-3231 . Inhibition of peptidyl-tRNA 
translocation by cycloheximide has been observed in 
certain cell-free systems [324,325], but the specific 
step blocked by the antibiotic in the initiation phase 
is still undetermined [325], although it inhibits re- 
association of the ribosome subunits [326] . Despite 
numerous reports indicating that cycloheximide does 
not inhibit peptide bond formation [ 179,25 1,269, 
324,325] there is a recent study postulating that 
peptidyl transferase is the target of cycloheximide 
[282]. Furthermore, the antibiotic has even been 
postulated as an inhibitor of chain termination 
[327]. 
Diphtheria toxin is a protein (mol.wt. 62 000) 
which, upon reduction of a disulphide bridge and 
hydrolysis of a peptide bond, leads to two poly- 
peptides (mol.wt. 24 000 and mol.wt. 38 000). This 
hydrolysis can be carried out in cell-free systems, but 
it also takes place when the diphtheria toxin enters a 
eukaryotic cell. The largest polypeptide fragment is 
involved in the penetration of the toxin into the cell, 
whereas the small one inhibits protein synthesis [l l] . 
Diphtheria toxin inhibits amino acid incorporation by 
mammalian cell-free systems [328] . NAD is absolute- 
ly required for the inhibitory action of the toxin 
[329], which takes place by inactivation of EF 2 
[330,33 l] and therefore prevents translocation 
[252,332]. The catalytic inactivation of EF 2 by 
diphtheria toxin takes place according to the reac- 
tion: 
EF 2+NAD’+ADP-ribose-EF 2-nicotinamide+I-F 
[333,335] 
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Diphtheria toxin has been reported to inhibit forma- 
tion of the ribosome-EF 2-GTP complex [336,337] 
and EF 2-dependent hydrolysis of GTP [333,336] ; 
but inhibition by the toxin of either ternary complex 
formation [338] or GTP hydrolysis [339] has not 
been confirmed by other workers. Although there are 
numerous reports showing a lack of effect of diphthe- 
ria toxin on bacterial systems [ 111, one group has 
repeatedly reported an effect of the toxin in bacterial 
cell-free systems [340]. 
synthesis by bacterial ribosomes since these anti- 
biotics inhibit the release factor(s)-dependent codon 
recognition [ 11,97,130,348,349] . Similarly thio- 
strepton is also an inhibitor of termination in bacterial 
systems probably by preventing the interaction of the 
release factor(s) with the ribosome [350]. 
Pederine inhibits protein synthesis in eukaryotic 
cells [341-3441 and cell-free systems [343,345]. 
The site of action of this compound is located on the 
ribosome [343,345]. Pederine at low concentrations 
causes reticulocyte polysome disaggregation, whereas 
at high concentrations prevents polysome breakdown 
and only partially inhibits release of growing peptides 
by puromycin [344]. It was, therefore, suggested 
that pederine might act at more than one site on the 
ribosome, by inhibiting mainly initiation and to a 
lesser extent translocation [344] . Studies on model 
systems have indeed clearly demonstrated an inhibi- 
tion of translocation even by low concentrations of 
pederine [252]. 
Peptidyl transferase is widely accepted to be in- 
volved not only in peptide bond formation (step (d)), 
but also in the peptidyl-tRNA hydrolysis reaction 
required for the termination phase. In fact all the 
peptidyl transferase inhibitors which have been test- 
ed, block termination in bacterial [ 11,97,130,348, 
349,351] and in mammalian [11,349,351,352] sys- 
tems, with the same specificity shown in peptide 
bond formation (figs. l-4). 
There is a report claiming that trichodermin might 
be a specific inhibitor of termination in eukaryotic 
protein synthesis [353]. However, it has been shown 
that trichodermin inhibits peptide bond fomation as 
well as termination [255,354]. Therefore specific 
inhibitors of the termination phase are not yet 
known. 
3.4. Miscellaneous inhibitors of translation 
The T’lophora alkaloids cryptopleurine, tylocre- 
brine and tylophorine are closely related in their 
chemical structure and mechanism of action. They 
are active in blocking protein synthesis by eukaryotic 
cells [34.5] and cell-free systems [346]. These alka- 
loids bind to eukaryotic ribosomes [346] on their 
60 S subunit [251] but were reported not to affect 
peptide bond formation [25 l] . These alkaloids have 
been shown to block the translocation step in cell- 
free systems from rabbit reticulocytes [347] and 
human tonsils (Carrasco, L. and Vazquez, D., unpub- 
lished results). In another work, however, it is report- 
ed that cryptopleurine is an inhibitor of peptide bond 
formation [282] ; but this might be an artefact of the 
system since cycloheximide is reported in the same 
study, to prevent peptide bond formation, and this 
finding contradicts all the previous observations by 
other workers. 
A number of aminochromes [355] and catechols 
(homogentisic acid and related compounds) [3$6] 
have been reported to inhibit poly U-directed phenyl- 
alanine incorporation by mammalian cell-free sys- 
tems. Adrenochrome is also active in E. coli cell-free 
systems at the ribosome level [357] . It inhibits 
aminoacyl-tRNA binding to human tonsil ribosomes 
[252]. However it is not yet known if this inhibition 
is due to an effect of adrenochrome in the codon- 
anticodon interaction. Therefore adrenochrome, 
besides inhibiting step (d), might be an inhibitor of 
the initiation phase. 
Step (g) 
Althiomycin inhibits protein synthesis by bacterial 
systems blocking the peptide bond formation step as 
shown in the puromycin [358] and the ‘fragment 
reaction’ assays (Cabrer, B. and San Millan, M.J., 
unpublished observations), and in the reaction of 
ribosome attached peptides with CACCA-Phe [359]. 
Althiomycin also blocks peptide bond formation in 
the intact bacteria [360]. 
As a consequence of their interaction with the Bacteriocin DFra is a protein, (mol.wt. 56 000) 
ribosome, streptomycin, and tetracycline have been produced by Enterobacter cloacae, the primary effect 
reported to block the termination phase of protein of which is the inhibition of protein synthesis in 
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intact bacteria [361]. Inhibition of MS2-RNA- 
directed amino acid incorporation by bacteriocin 
DF is has also been obserbed in cell-free systems 
[362]. 
Berninamycin is a peptide antibacterial antibiotic 
which inhibits protein synthesis in intact bacteria and 
bacterial cell-free systems [363]. Chartreusin is an 
antibiotic active in bacterial and eukaryotic systems. 
It prevents the enzymic binding of aminoacyl-tRNA 
to the ribosome [364]. 
Bottromycin AZ inhibits protein synthesis in in- 
tact cells and cell-free systems [365,366]. Bottro- 
mycin AZ acts on the larger ribosome subunit but has 
no effect on [‘4C]chloramphenicol binding [367]. 
The step mainly inhibited by bottromycin As is not 
yet known, although there are data suggesting an 
inhibition by the antibiotic of translocation [368] 
and step (cZ) in initiation [369]. Bottromycin As has 
also been reported to inhibit the puromycin [359] 
and the fragment [369] reactions but only to a limit- 
ed extent. 
Adsorption of colicin Es by sensitive bacteria 
results in a specific inhibition of protein synthesis 
[370] by inactivating the 30 S but not the 50 S ribo- 
somal subunit [37 l] . This inactivation of the 30 S 
subunit in intact bacteria is due to a specific cleavage 
of the 16 S rRNA near the 3’ terminal. Studies on 
cell-free systems have confirmed the cleavage by 
purified preparations of colicin Es of the 16 S ribo- 
somal RNA in the same position as it was previously 
observed working in intact cells [372,373]. Both the 
30 S and the 50 S ribosome subunits are required for 
this inactivation [374] which is inhibited by strepto- 
mycin, by tetracycline [375] and by an immunity 
factor prepared from extracts derived from colicino- 
genie cells [376] . Bacteria other than Enterobacteriu- 
ceae, are resistant to colicin Es but their ribosomes 
are sensitive in cell-free system [377]. Furthermore 
80 S type ribosomes from mouse ascites cells are 
sensitive to colicin E3 in cell-free systems [378]. 
Both the 40 S and the 60 S subunit are required for 
this inactivation, but only the 60 S subunit is dam- 
aged by colicin Es [378]. Colicin Es damaged ribo- 
somes are inactive in EF 2-dependent binding of 
aminoacyl-tRNA [378]. 
Emetine is an inhibitor of protein synthesis by 
80 S type ribosomes. Emetine was proposed early on 
as a structural analogue of cycloheximide [379] but 
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this was never confirmed by experimental evidence. 
Contrary to cycloheximide, direct interaction of 
emetine with the ribosomes has never been observed 
[25 1,380]. Enomycin inhibits protein synthesis by 
eukaryotic systems [25 1,381] . The antibiotic binds 
to the 40 S and the 60 S subunits [382]. 
The locus concerned with resistance to micro- 
coccin was mapped early on and shown to be located 
in a region of the Bacillus subtilis genome containing 
a number of ribosomal proteins, suggesting that the 
antibiotic might be an inhibitor of protein synthesis 
[383]. Micrococcin has indeed been shown to pre- 
vent protein synthesis. The antibiotic has been pro- 
posed as an inhibitor of translocation [360]. 
Multhiomycin is a sulphur containing antibiotic. It 
is an antibacterial compound which interacts with the 
ribosome and inhibits EF T-dependent aminoacyl- 
tRNA binding and GTP hydrolysis [384,385]. All the 
evidence suggests that multhiomycin can be consid- 
ered as a member of the thiostrepton group but the 
molecule is certainly smaller. Phenomycin is a basic 
polypeptide antibiotic very active as an inhibitor of 
protein synthesis on eukaryotic cells and cell-free 
systems. Little more is known about the mode of 
action of this antibiotic [386]. 
Antibiotics of the streptogramin B group (virido- 
grrsein, staphylomycin S, streptogramin B and syn- 
onyms) inhibit protein synthesis by bacterial cell-free 
systems [ 197,229-23 I] . Although it was shown 
ea.rly on that these antibiotics act on the 50 S ribo- 
some subunit [ l97,264,386a], little is known about 
the step specifically inhibited by these compounds. 
There is a study showing stimulation of f-Met-puro- 
mycin and inhibition of f-Met-Ala-puromycin by 
streptogramin B [386b] and therefore suggesting that 
formation of the first and the second peptide bond 
might be somehow different. 
Tubulosine is an alkaloid which specifically pre- 
vents protein synthesis by eukaryotic cells and cell- 
free systems [387]. Although it has been initially 
proposed that tubulosine might have a similar mode 
of action to cycloheximide, further studies do not 
support this hypothesis [3 161. 
Spectinomycin is an antibacterial aminoglycoside 
antibiotic which inhibits protein synthesis but, con- 
trary to those of the streptomycin group, does not 
cause misreading [388,389]. Resistance to spectino- 
mycin resides on the 30 S ribosome subunit 
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[388,390] and is due to an alteration of protein S5 
[302,390,392]. Since protein S5 is somehow involv- 
ed in the EF T- and EF G-dependent GTPase, spec- 
tinomycin has been proposed as an inhibitor of trans- 
location [393]. Recent results show that spectino- 
mycin is indeed an inhibitor of translocation in intact 
bacteria [360]. 
The compound N-tosyl-L-phenylalanylchloro- 
methane is an effective inhibitor of bacterial cell-free 
systems and has a selective action on EF T [394, 
3951. Ricin and abrin are two phytotoxin proteins 
(mol.wt. 65 000) of different origin which appear to 
have a similar mode of action [396,397]. Both toxins 
are inhibitors of protein synthesis by eukaryotic cells 
[398] and cell-free systems [399]. Although a pre- 
liminary .report has suggested that the action of ricin 
was probably located at the ribosome level [400] 
recent studies in more resolved systems have shown 
that both ricin and abrin inactivate EF 1 and EF 2 
and therefore inhibit binding of aminoacyl-tRNA as 
well as translocation (Carrasco, L. and Vazquez, D., 
unpublished observations). 
Showdomycin is a maleimide derivative which 
reacts with sulphydryl groups. Therefore this anti- 
biotic inhibits numerous reactions and is not-a selec- 
tive agent in intact cells. However showdomycin has 
been very useful in the study of the role of -SH 
groups, of EF 2 and the 60 S ribosome subunit, in 
elongation [401,402] . Other little studied inhibitors 
of protein synthesis are viomycin [403,404], kirro- 
mycin [405] and rubradirin [406] . 
The GTP analogue guanylyl methylenediphos- 
phonate has a methylene group in place of oxygen 
between the /3 and y phosphorus atoms thus prevent- 
ing enzymic cleavage at this position without major 
alteration of configuration. The structure of this 
analogue was designed to test the nature of the reac- 
tions involving GTP hydrolysis in protein synthesis. 
Since this GTP analogue was first shown to block 
poly U-directed polyphenylalanine synthesis [407] it 
has been repeatedly used in studies on protein synthe- 
sis in the different steps of the initiation, elongation 
and termination phases in which GTP hydrolysis is 
involved [ 11,408,409; reviews] . 
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